GO:0140954 histone H3K36 dimethyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140954 describes the enzymatic activity that successively adds two methyl groups to lysine 36 of histone H3, producing the H3K36me2 mark.
• NSD2 (also known as MMSET/WHSC1) is the principal histone H3K36 dimethyltransferase in humans, and its catalytic SET domain is required for H3K36me2 deposition.
• H3K36me2 is a chromatin mark associated with active gene bodies and is dysregulated in multiple cancers, including prostate cancer, pancreatic cancer, and lung cancer.
• The H3K36M oncohistone inhibits NSD2 and can activate a SETD2-dependent antiviral-like immune response in KRAS-driven lung cancer.
• NSD2-mediated H3K36me2 influences diverse biological processes, including lifespan regulation in C. elegans, cell durotaxis, ferroptosis, and NF-kB signaling.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are essential tools for dissecting the causal roles of H3K36 dimethyltransferases in disease.
Description
Histone H3 lysine 36 dimethylation (H3K36me2) is a chromatin modification that plays critical roles in transcriptional regulation, DNA repair, and cell fate determination. The enzyme responsible for depositing this mark is histone H3K36 dimethyltransferase, formally annotated as GO:0140954. This activity catalyzes the transfer of two methyl groups from S-adenosyl-L-methionine to lysine 36 of histone H3, generating H3K36me2. The mark serves as a docking site for reader proteins and influences chromatin accessibility, making it a central node in epigenetic signaling. In humans, the NSD family of proteins, particularly NSD2, carries out this reaction, and its dysregulation has been linked to cancer and developmental disorders. Researchers study GO:0140954 to understand how epigenetic marks are established and how they contribute to gene expression programs in health and disease. For example, NSD2-mediated H3K36me2 is required for the AR/FOXA1 neo-enhanceosome in prostate tumorigenesis, and its inhibition can alter oncogenic signaling. In pancreatic cancer, NSD2 regulates NF-kB signaling and suppresses Kras-driven tumorigenesis in a context-dependent manner. The H3K36M oncohistone, which inhibits NSD2, triggers an antiviral-like immune response in lung cancer, highlighting the therapeutic potential of targeting this activity. Beyond cancer, H3K36me2 has been implicated in aging, kidney disease, and ferroptosis, underscoring its broad biological significance. This article provides a comprehensive overview of GO:0140954, covering its definition, mechanism, key genes, disease associations, and research methodologies. By integrating authoritative QuickGO data with real PubMed literature, we aim to equip researchers with a clear understanding of this epigenetic mark and the tools available to study it.
histone H3K36 dimethyltransferase activity At A Glance
| GO ID | GO:0140954 |
|---|---|
| GO term | histone H3K36 dimethyltransferase activity |
| Ontology | molecular_function |
| Synonym | histone H3K36 dimethylase activity; histone H3-K36 dimethylation; histone H3K36 dimethylation; histone H3K36 mono/dimethylase activity; histone lysine N-dimethyltransferase activity (H3-K36 specific) |
| Major function | Catalyzes the successive addition of two methyl groups to lysine 36 of histone H3, producing H3K36me2 |
| Reaction | L-lysyl36-[histone H3] + 2 S-adenosyl-L-methionine = 2 H+ + N6,N6-dimethyl-L-lysyl36-[histone H3] + 2 S-adenosyl-L-homocysteine |
| Cofactor | S-adenosyl-L-methionine (SAM) as methyl donor |
| Substrate | Histone H3 with unmethylated or monomethylated lysine 36 |
| Product | Histone H3K36me2 and S-adenosyl-L-homocysteine |
What Is GO:0140954?
GO:0140954, histone H3K36 dimethyltransferase activity, is a molecular function defined as the catalysis of the reaction: L-lysyl36-[histone H3] + 2 S-adenosyl-L-methionine = 2 H+ + N6,N6-dimethyl-L-lysyl36-[histone H3] + 2 S-adenosyl-L-homocysteine. This reaction represents the successive addition of two methyl groups to the lysine residue at position 36 of histone H3, producing histone H3K36me2. The activity is also known as histone H3K36 dimethylase activity, histone H3-K36 dimethylation, histone H3K36 dimethylation, histone H3K36 mono/dimethylase activity, and histone lysine N-dimethyltransferase activity (H3-K36 specific).
Why Is histone H3K36 dimethyltransferase activity Important in Cell Biology?
Histone H3K36 dimethyltransferase activity is crucial for establishing the H3K36me2 epigenetic mark, which regulates gene expression, DNA repair, and cellular differentiation. Dysregulation of this activity is directly implicated in cancer, as NSD2 overexpression or mutation leads to altered H3K36me2 levels that drive oncogenic programs in prostate, pancreatic, and lung cancers. The H3K36M oncohistone, which inhibits NSD2, can reprogram immune responses in tumors, offering a potential therapeutic avenue. Beyond cancer, H3K36me2 influences lifespan in C. elegans, cell migration in kidney disease, and ferroptosis in keratinocytes, demonstrating its broad physiological relevance. Understanding this activity is therefore essential for both basic epigenetics and translational research.
• NSD2-mediated H3K36me2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in prostate tumorigenesis, making it a therapeutic target.
• The T1150A cancer mutant of NSD2 can introduce H3K36 trimethylation, altering the epigenetic landscape.
• NSD2 suppresses Kras-driven pancreatic tumorigenesis through multilevel regulation of NF-kB signaling.
• The H3K36M oncohistone inhibits NSD2 and activates a SETD2-dependent antiviral-like immune response in KRAS-driven lung cancer.
• NSD2 promotes cell durotaxis and drives the transition from polycystic kidney disease to tubulocystic renal cell carcinoma.
• NSD2 is a critical regulator of Erastin-induced ferroptosis in keratinocytes, linking H3K36me2 to oxidative stress responses.
• Muscle-specific H3K36 dimethyltransferase SET-18 shortens lifespan in C. elegans by repressing daf-16a expression.
• H3K36me2 is recognized by reader proteins that recruit chromatin modifiers and transcriptional regulators.
• Altered H3K36me2 levels are associated with developmental disorders and cancer progression.
• Targeting H3K36 dimethyltransferases with small molecules or CRISPR screens can reveal new therapeutic strategies.
What Happens During histone H3K36 dimethyltransferase activity?
Substrate Recognition and Binding
In simple terms: The enzyme first finds and binds to histone H3, specifically recognizing lysine 36.
Histone H3K36 dimethyltransferases, such as NSD2, contain a SET domain that recognizes the histone H3 tail. The enzyme binds to the nucleosome, positioning the target lysine 36 near the catalytic center. This binding is influenced by neighboring histone modifications and chromatin context. The specificity for H3K36 is determined by structural features of the SET domain and flanking regions, which ensure that only the correct residue is methylated.
Methyl Group Transfer
In simple terms: The enzyme uses SAM to add two methyl groups to lysine 36, one after the other.
The catalytic reaction proceeds via a sequential mechanism where S-adenosyl-L-methionine (SAM) serves as the methyl donor. The enzyme first transfers one methyl group to lysine 36, forming H3K36me1, and then a second methyl group to produce H3K36me2. This two-step process is processive, meaning the enzyme can perform both methylation events without releasing the substrate. The reaction releases S-adenosyl-L-homocysteine (SAH) as a byproduct.
Product Formation and Chromatin Association
In simple terms: The newly formed H3K36me2 mark stays on the histone and recruits other proteins that read the mark.
After dimethylation, H3K36me2 remains covalently attached to histone H3 and serves as a docking site for reader proteins containing PWWP, Tudor, or chromodomains. These readers can recruit transcriptional coactivators or chromatin remodelers, thereby influencing gene expression. The mark is also associated with active transcription, as it is enriched in gene bodies of actively transcribed genes.
Regulation and Turnover
In simple terms: The amount of H3K36me2 can go up or down depending on enzyme activity and removal by demethylases.
The levels of H3K36me2 are dynamically regulated by the balance between methyltransferases (writers) and demethylases (erasers). NSD2 activity can be modulated by interacting partners, post-translational modifications, and oncogenic mutations such as T1150A, which alters its product specificity. Additionally, the H3K36M oncohistone acts as a dominant-negative inhibitor of NSD2, reducing H3K36me2 levels and triggering compensatory pathways. Turnover of the mark is also influenced by cell cycle and developmental cues.
Key Genes Involved in GO:0140954 histone H3K36 dimethyltransferase activity
The following genes encode proteins with histone H3K36 dimethyltransferase activity or are directly involved in its regulation and downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NSD2 (MMSET/WHSC1) | Principal histone H3K36 dimethyltransferase in humans; deposits H3K36me2 | Implicated in prostate cancer, pancreatic cancer, kidney disease, and ferroptosis |
| NSD1 | H3K36 methyltransferase with overlapping functions | Associated with Sotos syndrome and cancer; potential redundancy with NSD2 |
| NSD3 (WHSC1L1) | H3K36 methyltransferase | Amplified in cancers; may compensate for NSD2 loss |
| SETD2 | H3K36 trimethyltransferase; acts downstream of H3K36me2 | Tumor suppressor; mutations in renal cell carcinoma and leukemia |
| SET-18 | C. elegans H3K36 dimethyltransferase | Regulates lifespan via daf-16a repression |
| H3F3A | Histone H3 variant; K36M mutation | Oncohistone that inhibits NSD2 and activates immune response |
| H3C1 | Histone H3; substrate for methylation | Provides the lysine 36 residue for modification |
| FOXA1 | Transcription factor; interacts with NSD2 in neo-enhanceosome | Required for AR/FOXA1-driven prostate tumorigenesis |
| AR | Androgen receptor; collaborates with NSD2 | Therapeutic target in prostate cancer |
| NF-kB | Signaling pathway regulated by NSD2 | Suppresses Kras-driven pancreatic tumorigenesis |
| Integrin/FAK/AKT | Signaling axis promoted by NSD2 | Drives durotaxis and kidney cancer progression |
| Erastin | Inducer of ferroptosis; NSD2 regulates response | Keratinocyte ferroptosis model |
| daf-16a | FOXO transcription factor in C. elegans | Repressed by SET-18, affecting lifespan |
| KRAS | Oncogene; context for H3K36M immune response | Lung and pancreatic cancer models |
| S-adenosyl-L-methionine (SAM) | Methyl donor cofactor | Essential for catalytic activity |
| S-adenosyl-L-homocysteine (SAH) | Byproduct of methylation reaction | Feedback inhibitor of methyltransferases |
| PWWP domain proteins | Readers of H3K36me2 | Mediate downstream chromatin effects |
| T1150A mutant NSD2 | Cancer-associated mutant with altered activity | Introduces H3K36 trimethylation |
How Is histone H3K36 dimethyltransferase activity Regulated?
Histone H3K36 dimethyltransferase activity is regulated at multiple levels. NSD2 expression can be induced by oncogenic signaling pathways, and its activity is modulated by interacting proteins such as AR and FOXA1 in prostate cancer. The T1150A mutation in NSD2 alters its catalytic specificity, leading to H3K36 trimethylation instead of dimethylation. Additionally, the H3K36M oncohistone acts as a competitive inhibitor of NSD2, reducing H3K36me2 levels and activating SETD2-dependent immune responses. In C. elegans, the SET-18 enzyme is regulated in a tissue-specific manner, with muscle-specific expression affecting lifespan through daf-16a repression. NSD2 also regulates NF-kB signaling, which in turn can feedback on its expression. Furthermore, NSD2 is involved in integrin/FAK/AKT signaling, which may influence its activity in kidney disease. In keratinocytes, NSD2 regulates ferroptosis, suggesting redox-dependent regulation.
histone H3K36 dimethyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NSD2 | Prostate cancer | CRISPR knockout of NSD2 in prostate cancer cell lines; H3K36me2 ChIP-seq |
| NSD2 | Pancreatic cancer | Conditional Nsd2 knockout in Kras-driven mouse models |
| H3F3A (H3K36M) | Lung cancer | Knock-in of H3K36M mutation in KRAS-driven lung cancer cells |
| NSD2 | Kidney disease / tubulocystic renal cell carcinoma | NSD2 overexpression in kidney epithelial cells; durotaxis assays |
| NSD2 | Ferroptosis in keratinocytes | NSD2 knockout or overexpression in keratinocytes treated with Erastin |
Prostate Cancer
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome, a transcriptional complex that drives prostate tumorigenesis. H3K36me2 deposited by NSD2 is essential for the recruitment of AR and FOXA1 to enhancers, promoting oncogenic gene expression. Targeting NSD2 or its catalytic activity could disrupt this complex and inhibit tumor growth.
Pancreatic Cancer
In pancreatic cancer, NSD2 suppresses Kras-driven tumorigenesis through multilevel regulation of NF-kB signaling. Loss of NSD2 enhances NF-kB activity and accelerates tumor formation, indicating a tumor-suppressive role in this context. This highlights the context-dependent functions of H3K36me2.
Lung Cancer
The H3K36M oncohistone inhibits NSD2, leading to reduced H3K36me2 and activation of a SETD2-dependent antiviral-like immune response in KRAS-driven lung cancer. This suggests that modulating H3K36me2 levels could sensitize tumors to immunotherapy.
Kidney Disease and Ferroptosis
NSD2 promotes cell durotaxis and drives the transition from polycystic kidney disease to tubulocystic renal cell carcinoma through integrin/FAK/AKT signaling. Additionally, NSD2 is a critical regulator of Erastin-induced ferroptosis in keratinocytes, linking H3K36me2 to oxidative stress and cell death pathways.
From histone H3K36 dimethyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NSD2 catalytic activity drive prostate tumorigenesis? | NSD2 knockout and catalytically dead mutant knock-in in prostate cancer cell lines |
| How does the T1150A mutation alter NSD2 function? | Point mutation knock-in of T1150A in NSD2-expressing cells |
| What is the role of H3K36me2 in pancreatic cancer? | Conditional Nsd2 knockout in Kras-driven pancreatic mouse models |
| Can H3K36M oncohistone activate immune response? | Knock-in of H3K36M in KRAS-driven lung cancer cells |
| Does NSD2 promote kidney cancer progression? | NSD2 overexpression in kidney epithelial cells and xenograft models |
| How does NSD2 regulate ferroptosis? | NSD2 knockout and overexpression in keratinocytes |
How to Study the histone H3K36 dimethyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genome-wide distribution of H3K36me2 | Mapping mark enrichment at genes and enhancers |
| Western blot | Global levels of H3K36me2 | Validating changes after knockout or overexpression |
| Immunofluorescence | Nuclear localization and colocalization | Visualizing mark in single cells |
| Mass spectrometry | Quantification of histone modifications | Detecting H3K36me2 and other marks |
| CRISPR screen | Identification of genes affecting H3K36me2 | Discovering synthetic lethal interactions |
| RNA-seq | Transcriptional changes upon manipulation | Assessing downstream effects on gene expression |
| ATAC-seq | Chromatin accessibility | Linking H3K36me2 to open chromatin regions |
| Co-immunoprecipitation | Protein-protein interactions | Identifying NSD2 complex partners |
Chromatin Immunoprecipitation Sequencing (ChIP-seq)
ChIP-seq using antibodies against H3K36me2 allows genome-wide mapping of the mark. This method reveals enrichment at gene bodies and enhancers, and can be used to assess changes upon NSD2 knockout or mutation. It is a standard approach for studying histone modifications.
Western Blot and Immunofluorescence
Western blot with anti-H3K36me2 antibodies quantifies global changes in the mark after genetic manipulation. Immunofluorescence can visualize nuclear distribution and colocalization with other chromatin marks. These methods are cost-effective and widely used for validation.
Mass Spectrometry-Based Proteomics
Mass spectrometry can detect and quantify histone modifications, including H3K36me2, with high precision. It can also identify interacting proteins and post-translational modifications on NSD2 itself. This approach is useful for unbiased discovery.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify genes that modulate H3K36me2 levels or synthetic lethality with NSD2 loss. Such screens have revealed context-specific dependencies in cancer cells. They are powerful for target discovery.
How CRISPR Can Be Used to Study GO:0140954 histone H3K36 dimethyltransferase activity
Knockout
CRISPR knockout of NSD2 or other H3K36 dimethyltransferases eliminates the enzyme, leading to loss of H3K36me2. This is used to study the consequences on gene expression, cell proliferation, and tumorigenesis. For example, NSD2 knockout in prostate cancer cells disrupts the AR/FOXA1 neo-enhanceosome and inhibits tumor growth. In pancreatic cancer, Nsd2 knockout enhances NF-kB signaling and accelerates Kras-driven tumorigenesis.
Point Mutation
Point mutations can be introduced to study catalytic activity or cancer-associated variants. The T1150A mutation in NSD2 alters its product specificity, enabling H3K36 trimethylation. CRISPR-mediated knock-in of such mutations allows precise dissection of their effects on chromatin and disease.
Knock-in
Knock-in of tagged NSD2 (e.g., FLAG or GFP) enables affinity purification and ChIP-seq with anti-tag antibodies. Knock-in of the H3K36M oncohistone in cancer cells inhibits NSD2 and activates immune responses. These models are valuable for studying localization and interactors.
Overexpression
Overexpression of wild-type or mutant NSD2 via CRISPR activation or lentiviral delivery increases H3K36me2 levels. This is used to model NSD2 amplification in cancers and to study gain-of-function phenotypes, such as increased cell migration in kidney disease or altered ferroptosis sensitivity.
How EDITGENE Supports histone H3K36 dimethyltransferase activity Research
Researchers studying histone H3K36 dimethyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for histone H3K36 dimethyltransferase activity research.
Frequently Asked Questions About histone H3K36 dimethyltransferase activity
What is histone H3K36 dimethyltransferase activity?
It is the enzymatic activity defined by GO:0140954 that catalyzes the addition of two methyl groups to lysine 36 of histone H3, producing H3K36me2.
What genes are involved in histone H3K36 dimethyltransferase activity?
The main genes include NSD2 (MMSET/WHSC1), NSD1, NSD3, and SETD2 in humans, as well as SET-18 in C. elegans.
Which enzyme deposits H3K36me2?
NSD2 is the principal histone H3K36 dimethyltransferase in humans, responsible for depositing the H3K36me2 mark.
What is the role of H3K36me2 in cancer?
H3K36me2 is associated with active transcription and is dysregulated in prostate, pancreatic, and lung cancers, where it influences oncogenic signaling and immune responses.
How is H3K36me2 different from H3K36me3?
H3K36me2 is dimethylation, while H3K36me3 is trimethylation. NSD2 primarily produces H3K36me2, whereas SETD2 catalyzes H3K36me3.
What diseases are linked to NSD2 mutations?
NSD2 mutations and overexpression are linked to prostate cancer, pancreatic cancer, kidney disease, and ferroptosis dysregulation.
Can CRISPR be used to study H3K36 dimethyltransferase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the function of NSD2 and related enzymes.
What is the H3K36M oncohistone?
H3K36M is a histone H3 mutation that inhibits NSD2, leading to reduced H3K36me2 and activation of a SETD2-dependent immune response in lung cancer.
How can I measure H3K36me2 levels?
Common methods include ChIP-seq, Western blot, immunofluorescence, and mass spectrometry.
Does NSD2 have non-catalytic functions?
Yes, NSD2 can act as a scaffolding protein in complexes such as the AR/FOXA1 neo-enhanceosome, independent of its catalytic activity.
Conclusion
Histone H3K36 dimethyltransferase activity (GO:0140954) is a fundamental epigenetic function that deposits the H3K36me2 mark, influencing gene expression, development, and disease. NSD2 is the primary enzyme responsible for this activity in humans, and its dysregulation is implicated in multiple cancers and other pathologies. Understanding the mechanisms, regulation, and disease relevance of H3K36me2 requires robust experimental models, including CRISPR-based knockout, point mutation, knock-in, and overexpression systems. EDITGENE offers comprehensive services to support such research, from custom cell line generation to library screening and bioinformatics analysis.
References
- 1. Su L et al.. 2018. Muscle-Specific Histone H3K36 Dimethyltransferase SET-18 Shortens Lifespan of Caenorhabditis elegans by Repressing daf-16a Expression.. Cell Rep 22(10):2716-2729 PMID: 29514099
- 2. Parolia A et al.. 2024. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.. Nat Genet 56(10):2132-2143 PMID: 39251788
- 3. Khella MS et al.. 2023. The T1150A cancer mutant of the protein lysine dimethyltransferase NSD2 can introduce H3K36 trimethylation.. J Biol Chem 299(6):104796 PMID: 37150325
- 4. Feng W et al.. 2024. Multilevel Regulation of NF-κB Signaling by NSD2 Suppresses Kras-Driven Pancreatic Tumorigenesis.. Adv Sci (Weinh) 11(30):e2309387 PMID: 38889281
- 5. Gladstein AC et al.. 2025. The H3 (K36M) oncohistone inhibits NSD2 to activate a SETD2-dependent antiviral-like immune response in KRAS-driven lung cancer.. bioRxiv PMID: 40501771
- 6. Feng W et al.. 2025. NSD2 promotes cell durotaxis and drives the transition from polycystic kidney disease to tubulocystic renal cell carcinoma through integrin/FAK/AKT signaling.. Oncogene 44(37):3437-3448 PMID: 40696168
- 7. Liu N et al.. 2026. NSD2 is a critical regulator of Erastin-induced ferroptosis in keratinocytes.. Free Radic Biol Med 255:194-205 PMID: 42462913
